Y-Intercept (HK)’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-82,483
| Closed | -$2.59M | – | 1653 |
|
|
2026
Q2 | $2.59M | Buy |
+82,483
| New | +$2.43M | 0.05% | 561 |
|
|
2026
Q1 | – | Sell |
-43,222
| Closed | -$1.01M | – | 1625 |
|
|
2025
Q4 | $1.01M | Sell |
43,222
-122,274
| -74% | -$2.72M | 0.02% | 978 |
|
|
2025
Q3 | $3.26M | Buy |
165,496
+152,925
| +1,216% | +$3.14M | 0.08% | 367 |
|
|
2025
Q2 | $273K | Buy |
+12,571
| New | +$297K | 0.01% | 1384 |
|
|
2025
Q1 | – | Sell |
-27,836
| Closed | -$581K | – | 1258 |
|
|
2024
Q4 | $581K | Buy |
+27,836
| New | +$598K | 0.04% | 662 |
|
|
2024
Q3 | – | Sell |
-40,174
| Closed | -$622K | – | 1386 |
|
|
2024
Q2 | $622K | Buy |
40,174
+23,792
| +145% | +$370K | 0.03% | 725 |
|
|
2024
Q1 | $261K | Buy |
16,382
+4,820
| +42% | +$72.6K | 0.02% | 1020 |
|
|
2023
Q4 | $194K | Sell |
11,562
-46,012
| -80% | -$629K | 0.02% | 1013 |
|
|
2023
Q3 | $673K | Buy |
+57,574
| New | +$770K | 0.07% | 453 |
|
|
2022
Q3 | – | Sell |
-18,563
| Closed | -$130K | – | 1014 |
|
|
2022
Q2 | $130K | Buy |
+18,563
| New | +$136K | 0.02% | 709 |
|
Other funds holding CPRX
Y-Intercept (HK)'s CPRX Position: Q3 2026 in Review
Y-Intercept (HK) sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 82,483 shares — an estimated $2.59M sold.
Y-Intercept (HK) first reported a position in CPRX in Q2 2022 and held it in 10 quarters. The position peaked at $3.26M in Q3 2025. 1 fund tracked by Wall St. Rank holds CPRX as of Q3 2026.
- Y-Intercept (HK) reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
- Y-Intercept (HK) sold 82,483 Catalyst Pharmaceutical shares in Q3 2026, an estimated $2.59M.
- Y-Intercept (HK) first reported a position in Catalyst Pharmaceutical in Q2 2022 and held it in 10 quarters.
- Y-Intercept (HK)'s Catalyst Pharmaceutical position peaked at $3.26M in Q3 2025.
- 1 fund tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.
Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.